Cited by 296Glioma Diagnosis and TreatmentCancer, Hypoxia, and MetabolismAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 62 of the 63 references it cites were found in a registry or an index.

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Yen, K E, Bittinger, M A, Su, S M, Fantin, V R·2010·Oncogene

DOI 10.1038/onc.2010.444

Open this paper in CoChat — free account

Abstract

The discovery of somatic mutations in the isocitrate dehydrogenase (IDH) enzymes through a genome-wide mutational analysis in glioblastoma represents a milestone event in cancer biology. The nature of the heterozygous, point mutations mapping to arginine residues involved in the substrate binding inspired several research teams to investigate their impact on the biochemical activity of these enzymes. Soon, it became clear that the mutations identified impaired the ability of IDH1 and IDH2 to catalyze the conversion of isocitrate to α-ketoglutarate (αKG), whereas conferring a gain of a novel enzymatic activity leading to the reduction of αKG to the metabolite D2-hydroxyglutarate (D-2HG). Across glioma as well as several hematologic malignancies, mutations in IDH1 and IDH2 have shown prognostic value. Several hypotheses implicating the elevated levels of D-2HG and tumorigenesis, and the therapeutic potential of targeting mutant IDH enzymes will be discussed.

Integrity signals

Registry

Crossref · 10.1038/onc.2010.444

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citation
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337

Flagged first, then by citations

Show all 63 references

1 of the 63 references couldn’t be matched to a known paper.

Sorted by citations

Items 201–296 of 296

Molecular markers in Gliomas: A practical review and algorithm proposal
Ocampo-Navia, M. I., Marín-Navas, F., Agudelo-Arrieta, M., Taub-Krivoy, A., & Lee, O. H. F. (2025) · Interdisciplinary Neurosurgery · doi:10.1016/j.inat.2025.102062 · Cited by 9
Evaluating ivosidenib for the treatment of acute myeloid leukemia
Donker, M. L., & Ossenkoppele, G. J. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1806822 · Cited by 9
Exploring the key genes and pathways in enchondromas using a gene expression microarray
Shi, Z., Zhou, H., Pan, B., Lu, L., Kang, Y., Liu, L., Wei, Z., & Feng, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16700 · Cited by 9
Génétique et gliomes cérébraux
Alentorn, A., Labussière, M., Sanson, M., Delattre, J., Hoang‐Xuan, K., & Idbaïh, A. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2012.05.013 · Cited by 8
Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants
Yao, K., Liu, H., Liu, P., Liu, W., Yang, J., Wei, Q., Cao, P., & Lai, Y. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107261 · Cited by 7
Normalization of metabolic data to total thymine content and its application to determination of 2-hydroxyglutarate
Modrzejewska, M., Gawroński, M., & Gackowski, D. (2021) · Analytical Biochemistry · doi:10.1016/j.ab.2021.114129 · Cited by 7
Molecular biomarkers of glioblastoma: current targets and clinical implications
Yoshimoto, K., Mizoguchi, Hata, Amano, Nakamizo, & Sasaki (2012) · Current Biomarker Findings · doi:10.2147/cbf.s25590 · Cited by 7
3D-QSAR, molecular docking and molecular dynamics simulations study of 3-pyrimidin-4-yl-oxazolidin-2-one derivatives to explore the structure requirements of mutant IDH1 inhibitors
Yao, K., Liu, P., Liu, H., Wei, Q., Yang, J., Cao, P., & Lai, Y. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.03.092 · Cited by 8
Metabolic Adaptations and Functional Activity of Macrophages in Homeostasis and Inflammation
Yurakova, T. R., Gorshkova, E. A., Nosenko, M. A., & Drutskaya, M. S. (2024) · Biochemistry (Moscow) · doi:10.1134/s0006297924050043 · Cited by 7
A fluorescence ‘turn-on’ detection of α-ketoglutaric acid with silole as the fluorescence reporter
Zhan, C., Zhang, G., & Zhang, D. (2017) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2017.08.017 · Cited by 6
New therapeutic strategies for high-risk acute myeloid leukemia
Menghrajani, K. N., & Tallman, M. S. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000409 · Cited by 7
Endocannabinoids are potential inhibitors of glioblastoma multiforme proliferation
Duzan, A., Reinken, D. N., McGomery, T. L., Ferencz, N. M., Plummer, J. M., & Basti, M. M. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.01.005 · Cited by 7
Activating Mutations and Targeted Therapy in Cancer
Tuna, M., & Christopher, I. L. (2012) · InTech eBooks · doi:10.5772/48701 · Cited by 8
Polymorphisms in Genes of Tricarboxylic Acid Cycle Key Enzymes Are Associated with Early Recurrence of Hepatocellular Carcinoma
Wan, S., Wu, Y., Zhou, X., Chen, Y., An, J., Yu, X., Zhang, H., Yang, H., & Xing, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124471 · Cited by 7
Familial hematological malignancies: new IDH2 mutation
Hamadou, W.-S., Bourdon, V., Letard, S., Brenet, F. A., Laarif, S., Besbes, S., Paci, A., David, M. D., Penard‐Lacronique, V., Youssef, Y. B., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2813-9 · Cited by 7
Novel therapeutic compound acridine–retrotuftsin action on biological forms of melanoma and neuroblastoma
Cichorek, M., Ronowska, A., Gensicka‐Kowalewska, M., Deptuła, M., Pelikant‐Małecka, I., & Dzierzbicka, K. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2776-4 · Cited by 7
Evidence-based Treatment for Low-grade Glioma
Semmel, D., Ware, C., Kim, J. Y., & Peters, K. B. (2018) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2018.10.008 · Cited by 8
A smartphone-assisted test paper fluorescence sensing platform for visual detection of α-Ketoglutaric acid based on Metal-Organic frameworks
Zhang, J., Qin, B., Song, L., & Hong, H. (2024) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2024.125222 · Cited by 6
Profiling Inhibitor Scaffolds for the Cancer Target Jumonji‐C Domain‐Containing Protein 6
Corner, T. P., Salah, E., Tumber, A., Holt‐Martyn, J. P., Brewitz, L., & Schofield, C. J. (2025) · ChemMedChem · doi:10.1002/cmdc.202500682 · Cited by 6
Understanding the Enemy
Velculescu, V. E., & Diaz, L. A. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003001 · Cited by 6
Genetic Variants in Genes of Tricarboxylic Acid Cycle Key Enzymes Predict Postsurgical Overall Survival of Patients with Hepatocellular Carcinoma
Du, X., Wan, S., Chen, Y., Qü, P., Huang, X., Yu, X., Yang, H., Zhang, Y., & Xing, J. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3876-2 · Cited by 6
Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia
Bories, P.-N., Nakib, S., Cynober, L., Alary, A., Coudé, M.-M., Chevillon, F., Tamburini, J., Birsen, R., Kosmider, O., & Bouscary, D. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0427 · Cited by 5
Determination of TMPRSS2‐ERG, SPOP, FOXA1, and IDH1 prostate cancer molecular subtypes in Colombian patients and their possible implications for prognosis
Ovalle, W. J. M., Sanabria‐Salas, M. C., Mesa, J., Varela‐Ramírez, R., Moreno, Y. Y. S., Sánchez‐Villalobos, S. A., Lemus, M. N., & Serrano, M. L. (2023) · Cell Biology International · doi:10.1002/cbin.12000 · Cited by 5
Mechanisms of Aggressiveness in Glioblastoma: Prognostic and Potential Therapeutic Insights
Celine, S., Lourenço, T., Xavier‐Magalhães, A., Pojo, M., & Bruno, M. (2013) · InTech eBooks · doi:10.5772/52361 · Cited by 5
Discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates
Zhang, Z., Liu, Y.-K., Luo, Z., Wu, M., Evans, C. N., Qu, Z., Xue, F., Wang, Z., Stanciu, L., Zhang, Z., et al. (2026) · Nature Chemistry · doi:10.1038/s41557-026-02093-x · Cited by 7
IDH1 Mutation Impacts DNA Repair Through ALKBH2 Rendering Glioblastoma Cells Sensitive to Artesunate
Switzeny, O. J., Pusch, S., Christmann, M., & Kaina, B. (2025) · Biomedicines · doi:10.3390/biomedicines13061479 · Cited by 4
Molecular Pathology
Ho, C., & Kluk, M. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.04.011 · Cited by 4
Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation
Heiblig, M., Khalife‐Hachem, S., Willekens, C., Micol, J., Paci, A., Penard‐Lacronique, V., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1831909 · Cited by 4
Investigation of Isocitrate Dehydrogenase 1 and 2 Mutations in Acute Leukemia Patients in Saudi Arabia
Alkhatabi, H. A., Saddeq, H. A. B., Alyamani, L., Shinawi, T., Yasin, E. B., Alserihi, R. F., Felimban, R. I., Tayeb, H. H., Mimani, R., Alalla, Z., et al. (2021) · Genes · doi:10.3390/genes12121963 · Cited by 4
The Cancer Driver Genes IDH1 and IDH2 and CD204 in WHO-Grade 4 Astrocytoma: Crosstalk Between Cancer Metabolism and Tumour Associated Macrophage Recruitment in Tumour Microenvironment
Kurdi, M. E., Mulla, N., Katib, Y., Alsinani, T., Hakamy, S., Addas, B. M. J., Malibary, H. M., Halawa, T. F., Farhan, M. S., Faizo, E., et al. (2023) · Biologics · doi:10.2147/btt.s394556 · Cited by 4
Inhibition of Cancer Metabolism: a Patent Landscape
Katt, W. P., & Cerione, R. A. (2019) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2019-0012 · Cited by 4
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to haveIDH1orIDH2mutations
Benton, C. B., Ravandi, F., Andreeff, M., Kadia, T. M., Ruvolo, V. R., Qiu, P., Wheeler, D. A., Garcia‐Manero, G., Cortes, J. E., Kantarjian, H. M., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.840777 · Cited by 4
Proteomic Analysis of Differences in Ectoderm and Mesoderm Membranes by DiGE
Wang, R., Liu, X., Küster-Schöck, E., & Fagotto, F. (2012) · Journal of Proteome Research · doi:10.1021/pr300379m · Cited by 4
Energy metabolism-related GLUD1 contributes to favorable clinical outcomes of IDH-mutant glioma
Deng, R., Qin, J., Wang, L., Li, H., Wen, N., Qin, K., Dong, J., Wu, J., Zhu, D., & Sun, X. (2024) · BMC Neurology · doi:10.1186/s12883-024-03787-w · Cited by 3
Targeting IDH1 mutation-driven Nrf2 signaling to suppress malignant behavior in fibrosarcoma cells
Park, S., Chun, K., & Kim, D. (2025) · Toxicological Research · doi:10.1007/s43188-025-00284-1 · Cited by 3
Systems-Level Analysis of Cancer Metabolism
Gameiro, P. A., Metallo, C. M., & Stephanopoulos, G. N. (2012) · Springer eBooks · doi:10.1007/978-94-007-4534-6_11 · Cited by 3
Clinical Applications of Molecular Markers in Bone Tumors
Hameed, M. (2015) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000091 · Cited by 3
2-Hydroxyglutarate as an MR spectroscopic predictor of an IDH mutation in gliomas
Bauer, J., Raum, H. N., Kugel, H., Müther, M., Mannil, M., & Heindel, W. L. (2024) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-2285-4923 · Cited by 3
Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
Pasquier, F., Chahine, C., Marzac, C., & de Botton, S. (2020) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2020.1792286 · Cited by 3
Evolvement of Molecular Biomarkers in Targeted Therapy of Malignant Gliomas
Hlavin, E. M., Hadziahmetovic, M., & Chakravarti, A. (2011) · InTech eBooks · doi:10.5772/22985 · Cited by 5
Parallel evolution of IDH2 gene in cetaceans, primates and bats
Ai, W., Chen, S., Chen, X., Shen, X., & Shen, Y. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.12.005 · Cited by 3
A liquid biopsy platform for detecting gene-gene fusions as glioma diagnostic biomarkers and drug targetsPreprint
Palande, V., Detroja, R., Gorohovski, A., Glaß, R., Flueh, C., Kurtz, M., Perez, S., Shay, D. R., Siegal, T., & Frenkel‐Morgenstern, M. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.25.963975 · Cited by 3
Platinum Sensitivity inIDH1/2Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
Doroshow, D. B., Wei, W., Mehrotra, M., Sia, D., Eder, J. P., Bindra, R. S., Houldsworth, J., LoRusso, P. M., & Walther, Z. (2023) · Cancer Investigation · doi:10.1080/07357907.2023.2242957 · Cited by 2
Current trends in Glioblastoma
Koçak, M., Atasoy, Ö., Çini, N., & Erbaş, O. (2021) · Demiroglu Science University Florence Nightingale Journal of Medicine · doi:10.5606/fng.btd.2021.25074 · Cited by 2
Aberrant HIF1- α and SIX-1 Expression is Associated with Poor Prognosis in Acute Myeloid Leukemia Patients with Isocitrate Dehydrogenase 1 Mutations
Ali, T. M., Usman, R., Shah, S. A., Parvez, A., Anwar, S., Muneer, Z., & Saeed, M. (2024) · Cancer Control · doi:10.1177/10732748241271714 · Cited by 2
Molecular insights and functional analysis of isocitrate dehydrogenase in two gram-negative pathogenic bacteria
Xiong, W., Su, R., Han, X., Zhu, M., Tang, H., Huang, S., Wang, P., & Zhu, G. (2024) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-024-04169-7 · Cited by 2
Isocitrate dehydrogenase 1 gene variants analysis of glioma patients from Pakistan
Naz, H., Bashir, Q., Rashid, N., & Shahzad, N. (2020) · Annals of Human Genetics · doi:10.1111/ahg.12409 · Cited by 1
The Heterogeneous Interplay Between Metabolism and Mitochondrial Activity in Colorectal Cancer
Desterke, C., Fu, Y., Mata-Garrido, J., Hamaï, A., & Chang, Y. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120571 · Cited by 1
Toluquinol, A Marine Fungus Metabolite, Inhibits Some of the Hallmarks of Cancer
García‐Caballero, M., Medina, M. Á., & Quesada, A. R. (2014) · Springer eBooks · doi:10.1007/978-3-319-07145-9_14 · Cited by 1
Gliomas: marcadores tumorais e prognóstico
da Silva, V. T. G., Picarelli, H., Figueiredo‬‬‬, E. G., & Teixeira, M. J. (2012) · Arquivos Brasileiros de Neurocirurgia Brazilian Neurosurgery · doi:10.1055/s-0038-1625666 · Cited by 1
Molecular Determinants of Gastrointestinal Cancers
Battaglin, F., Randon, G., Raimondi, A., Pagani, F., Arai, H., Pietrantonio, F., & Lenz, H. (2021) · Advances in Oncology · doi:10.1016/j.yao.2021.02.026 · Cited by 1
Tumors of the Glia: Recent Advances
Suri, V. S., Mahajan, S., Singh, J., Dandapath, I., Chakraborty, R., Khan, A., Sharma, M. C., & Sarkar, C. (2022) · Springer eBooks · doi:10.1007/978-981-16-8313-8_13 · Cited by 1
In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903
Tong, Z., Yerramilli, U., Yao, S. Y. M., Young, J. D., Hoffmann, M., & Surapaneni, S. (2018) · Xenobiotica · doi:10.1080/00498254.2018.1539783 · Cited by 1
MRS for D-2HG Detection in IDH-Mutant Glioma
Andronesi, O. C., Batchelor, T. T., & Cahill, D. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-27359-0_11 · Cited by 1
Advances in New Targets for Differentiation Therapy of Acute Myeloid Leukemia
Yao, J., Zhao, M., Wang, J., & Wei, L. (2020) · Journal of cancer research updates · doi:10.30683/1929-2279.2020.09.10 · Cited by 1
Atypical cartilage in type II germ cell tumors of the mediastinum show significantly different patterns of IDH1/2 mutations from conventional chondrosarcoma
Warmke, L. M., Liang Cheng, C., Sperling, R. M., Sen, J. D., & Ulbright, T. M. (2022) · Modern Pathology · doi:10.1038/s41379-022-01106-7 · Cited by 1
PV, ET, PMFの分子病態と治療概論
小松, 則. (2012) · 臨床血液 · doi:10.11406/rinketsu.53.1589
MOLECULAR ASPECTS OF ENDOTHELIAL CELL FUNCTION AND HYPOXIA-DEPENDENT TUMOR ANGIOGENESIS
Kucharzewska, P. (2011)
BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Patient Serum With Glioma and Cerebrospinal Fluid Extracellular Vesicles
Chen, W. W., Balaj, L., Liau, L. M., Samuels, M. L., Kotsopoulos, S., Maguire, C. A., LoGuidice, L., Soto, H., Garrett, M. C., Zhu, L. D., et al. (2013)
Chondroma arising from the spinal dura mater at the thoracic level: A case report with molecular analysis
Miyazaki, M., Yashiro, K., Tanino, M. A., Tanaka, S., & Fujioka, Y. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.003
MicroRNA-183 upregulates HIF-1a by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
TanakaTakashi, H., & NishiharaKatsu, M. (2013)
METHODS: ORIGINAL ARTICLE BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles
Chen, W. W., Balaj, L., Liau, L. M., Samuels, M. L., Kotsopoulos, S. K., Maguire, C. A., LoGuidice, L., Soto, H., Garrett, M. C., Zhu, L. D., et al. (2013)
Genetic Profiling of Phaeochromocytoma and Paraganglioma Using Next Generation Sequencer
Pillai, S. (2017) · Griffith Research Online · doi:10.25904/1912/1252
Estudo da expressão dos genes TETs e níveis de hidroximetilação em meduloblastoma
Salomão, K. B. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2018.tde-18042018-104554
Current and Emerging Medical Therapies for Advanced Disease in Intrahepatic Cholangiocarcinoma
Deng, A., & Cohen, S. J. (2018) · Springer eBooks · doi:10.1007/978-3-319-91977-5_11
Glioblastoma with a primitive neuronal component in a long-term surviving patient
Jirásek, T., Šedivcová, M., Vaněček, T., Grossmann, P., Šteiner, P., Fröhlichová, L., Švajdler, M., Engelová, J., Emmerová, R., Brabec, R., et al. (2019) · Onkologie · doi:10.36290/xon.2019.017
Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G., & Sosman, J. (2019) · Cutaneous Melanoma · doi:10.1007/978-3-319-46029-1_55-1
Recently approved molecularly targeted therapies in AML
Papadantonakis, N., & Erba, H. P. (2019) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.76
Behandlung von Gliomen - die neurochirurgische Perspektive
Holling, M., Grauer, O. M., Brokinkel, B., & Stummer, W. (2020) · Im Focus Onkologie · doi:10.1007/s15015-020-2504-1
Magnetic Resonance for non-invasive evaluation of preclinical models of human brain tumors
Hamans, B. C. (2015) · Radboud Repository (Radboud University)
Análisis de alteraciones moleculares de SPOP, FOXA1 e IDH1 en cáncer de próstata de población colombiana y sus posibles implicaciones en el pronóstico
Ovalle, M., & Johana, W. (2021)
The Mevalonate Pathway: A Potential Therapeutic Target for JAK2-driven Myeloproliferative Neoplasms
Griner, L. N. (2013) · Digital Commons - University of South Florida (University of South Florida)
Treatment of Acute Myeloid Leukemia: A Concise Overview
(2020) · Abasyn Journal Life Sciences · doi:10.34091/ajls.3.2.11
The Clinical Frailty Scale as Predictor of Overall Survival After Resection of High-grade GliomaPreprint
Klingenschmid, J., Krigers, A., Pinggera, D., Kerschbaumer, J., Thomé, C., & Freyschlag, C. F. (2022) · Research Square · doi:10.21203/rs.3.rs-1243317/v1
Machine learning for healthcare with a focus on the early diagnosis of epilepsy and brain tumor detection
Lu, D. (2022) · doi:10.21248/gups.67966
Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma
Chandra, S., McArthur, G. A., & Sosman, J. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_55
Anti-cancer Activity of Vitamin-C Against Leukemia: A Review
Gupta, T., Vishwakarma, V. K., & Khan, M. K. M. |. K. (2018) · International Journal of Trend in Scientific Research and Development · doi:10.31142/ijtsrd14250
Faculty Opinions recommendation of IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives.
Choate, K. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.726744181.793558674
Biology of Cancer
Alsiary, R., Katouah, H. A., Al-Amodi, H. S. A. B., & Al-Toub, M. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080384123010007
Applications of AI in Identifying and Predicting Glioblastoma and Related Brain Cancers Using Genetic BiomarkersPreprint
Raman, A. N., & Chowlur, S. (2023) · doi:10.31219/osf.io/ed85p
การศึกษาอัตราการตรวจพบการกลายพันธุ์ของยีน Isocitrate dehydrogenase ชนิดที่ 1 และ ชนิดที่ 2 ในผู้ป่วยโรคมะเร็งท่อน้ำดีชนิดภายในตับและมะเร็งท่อน้ำดีชนิดภายนอกตับในประเทศไทย
สุทธิประภา, ภ. (2016) · doi:10.58837/chula.the.2016.1264
A Smartphone-Assisted Test Paper Fluorescence Sensing Platform Based on Metal Organic Framework for Visual Detection of Α‑Ketoglutaric AcidPreprint
Zhang, J., Qin, B., Song, L., & Hong, H. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4803210
Spectrum of Findings Seen in Patients With IDH1/2-Mutant Cholangiocarcinoma
Kierans, A. S., Lutfi, A., Afghan, M. K., Khan, S., Javaid, S., Currie, B. M., Rocca, J. P., Samstein, B., Golden, E. B., Popa, E., et al. (2024) · International Journal of Surgical Pathology · doi:10.1177/10668969241271397
Metabolic changes and functional activity of macrophages in homeostasis and in inflammation (review)
Yurakova, T. R., Gorshkova, E. A., Nosenko, M. A., & Drutskaya, M. S. (2024) · Biochemistry (Moscow) · doi:10.31857/s0320972524050047
Molecularly driven therapies in the treatment of primary brain tumors
Nasany, R. A., & de la Fuente, M. I. (2025) · Advances in cancer research · doi:10.1016/bs.acr.2025.05.005
Brain–CNS cancer: Biomarker landscape
Prajapati, V. D., Verma, M., & Roy, S. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33902-8.00018-3
Pathoepigenetics of brain tumors and prevalent neoplasms
Cacabelos, R., Naidoo, V., Tellado, I., Cacabelos, N., Cacabelos, P., Corzo, L., Fernández‐Novoa, L., & Martínez-Iglesias, O. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-18722-3.00047-5
Overview of RNA-sequencing and applications to neuro-oncology
Patel, H. M., Chaudhary, A., Venugopal, C., Singh, S. K., & Escudero, L. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27356-8.00080-2
Etude des sous-unités a de la v-ATPase : caractérisation de leurs interactions avec les protéines SNAREs et étude de l’expression par des gliomes de la sous-unité rénale a4
Gleize, V. (2011) · theses.fr (ABES) · doi:10.70675/54c69fedzabbaz4bd3zac98z7a3d2ac7948e
Génomique intégrée des neuroblastomes olfactifs : implications anatomopathologiques et thérapeutiques
Classe, M. (2017) · theses.fr (ABES) · doi:10.70675/e9d57129zf812z42c4zb161zf119c8d906c3
Characterization of cellular heterogeneity in Diffuse Low Grade Glioma
Augustus, M. (2020) · theses.fr (ABES) · doi:10.70675/037c23a4z44ddz4bb7z999ezb0c178c35170
The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis
Dickerman, R. D., Mendoza, M., McClinton, M., Champion, G., Runnels, J., & Hudson, H. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2688939
BindingDB Entry 50013577: Discovery and Optimization of 2
BindingDB (2022) · UC San Diego · doi:10.7270/q2ff3x3s
BindingDB Entry 50020431: Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.
BindingDB (2024) · UC San Diego · doi:10.7270/q24x5d75
BindingDB Entry 50040796: Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.
BindingDB (2013) · UC San Diego · doi:10.7270/q2x92cf7
The Identification and Characterisation of Novel Proteins and Metabolic Signalling Pathways that Regulate TRAIL-Induced Apoptosis
Robinson, G. L. (2012) · Leicester Research Archive (University of Leicester)

Authors: Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R.
Affiliations: Agios Pharmaceuticals (United States) (US)
Corresponding author: Fantin, V R
ORCID: Yen, K E
Fantin, V R
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2010-10-25
Volume: 29
Issue: 49
Pages: 6409-6417
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2010.444
OpenAlex: W2002134084
Cited by: 296
References: 63
Citations by year: 2026: 3 · 2025: 8 · 2024: 11 · 2023: 17 · 2022: 16 · 2021: 23 · 2020: 21 · 2019: 21 · 2018: 22 · 2017: 23 · 2016: 16 · 2015: 16 · 2014: 18 · 2013: 29 · 2012: 27
FWCI: 2.93
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: IDH mutation, IDH1, IDH2, glioblastoma, glioma, hematologic malignancies, gain-of-function mutations, alpha-ketoglutarate, prognostic factors, carcinogenesis
MeSH terms: Glioma, Glutarates, Humans, Isocitrate Dehydrogenase, Oncogenes, Biomarkers, Tumor, Central Nervous System Neoplasms, Point Mutation, Hematologic Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cancer-associated IDH mutations: biomarker and therapeutic opportunities

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks